Acumen Pharmaceuticals Inc
NASDAQ:ABOS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Acumen Pharmaceuticals Inc
NASDAQ:ABOS
|
US |
|
S
|
Sobute New Materials Co Ltd
SSE:603916
|
CN |
|
Cannabix Technologies Inc
OTC:BLOZF
|
CA |
|
Razer Inc
HKEX:1337
|
US |
Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc. discovers and develops medicines and diagnostics for Alzheimer's disease. The company is headquartered in Charlottesville, Virginia and currently employs 14 full-time employees. The company went IPO on 2021-07-01. The firm is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The firm is focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in early AD patients. The firm's ACU193 is a humanized monoclonal antibody that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The firm's therapeutic approach focuses on targeting AbOs, which is a toxic and pathogenic form of Ab relative to Ab monomers and amyloid plaques.
Acumen Pharmaceuticals, Inc. discovers and develops medicines and diagnostics for Alzheimer's disease. The company is headquartered in Charlottesville, Virginia and currently employs 14 full-time employees. The company went IPO on 2021-07-01. The firm is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The firm is focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in early AD patients. The firm's ACU193 is a humanized monoclonal antibody that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The firm's therapeutic approach focuses on targeting AbOs, which is a toxic and pathogenic form of Ab relative to Ab monomers and amyloid plaques.
ALTITUDE on track: Acumen said its Phase II ALTITUDE-AD study of sabirnetug is tracking to plan, with retention and rollover into the open-label extension described as strong and in line with other recent Alzheimer’s trials.
Readout coming: The company still expects top-line ALTITUDE-AD data late this year, including key efficacy and safety results.
EBD momentum: Acumen’s enhanced brain delivery program with JCR showed preclinical data the company said exceeded its target profile, helped support multiple candidate molecules, and led to a roughly $36 million private placement.
Strong balance sheet: The company ended 2025 with $116.9 million in cash and marketable securities, which it says funds operations into early 2027.
Losses widened with trial work: 2025 R&D spending rose to $104.9 million, mainly because of ALTITUDE-AD manufacturing and materials plus EBD research, while G&A fell to $18.9 million.
Phase III thinking: Management said its base case, if ALTITUDE is positive, is one additional Phase III study with a design similar to ALTITUDE-AD and a larger population, based on early FDA discussions.
